08/11/23 8:30 AMNasdaq : SBFM, SBFMW earningslow floatSunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly reportRHEA-AIneutral
05/16/23 9:58 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-MarketSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to aRHEA-AIneutral
05/12/23 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-MarketSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreementRHEA-AIneutral
05/11/23 9:00 AMNasdaq : SBFM, SBFMW earningslow floatSunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. TheRHEA-AIneutral
04/05/23 8:00 AMNasdaq : SBFM, SBFMW earningslow floatSunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate UpdateSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal yearRHEA-AIneutral
02/28/23 7:30 AMNasdaq : SBFM, SBFMW covid-19low floatSunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 TreatmentSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of an exclusive worldwide license agreementRHEA-AIvery positive
02/10/23 7:35 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer CompoundSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir MortimerRHEA-AIneutral
01/19/23 7:30 AMNasdaq : SBFM, SBFMW buybacklow floatSunshine Biopharma Announces Share Repurchase ProgramSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a shareRHEA-AIneutral
12/20/22 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma’s Annual Letter to ShareholdersSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve Slilaty, ChairmanRHEA-AIpositive
11/16/22 8:00 AMNasdaq : SBFM, SBFMW low floatSunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA ProjectSunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreementRHEA-AIvery positive
